

Jiaxin Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3192170/publications.pdf>

Version: 2024-02-01

54
papers

863
citations

623734

14
h-index

580821

25
g-index

74
all docs

74
docs citations

74
times ranked

1383
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease. <i>Rheumatology</i> , 2022, 61, 815-825.	1.9	5
2	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. <i>Clinical Infectious Diseases</i> , 2022, 74, 734-742.	5.8	88
3	Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease. <i>Rheumatology</i> , 2022, 61, 2197-2209.	1.9	3
4	SMO3, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2022, 61, 1841-1848.	1.9	3
5	Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis. <i>Clinical Rheumatology</i> , 2022, , 1.	2.2	2
6	Prediction of new organ onset in recurrent immunoglobulin G4-related disease during 10 years of follow-up. <i>Journal of Internal Medicine</i> , 2022, 292, 91-102.	6.0	3
7	Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome. <i>Rheumatology</i> , 2022, 61, e277-e279.	1.9	2
8	Case Fatality Risk of the First Pandemic Wave of Coronavirus Disease 2019 (COVID-19) in China. <i>Clinical Infectious Diseases</i> , 2021, 73, e79-e85.	5.8	50
9	Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients. <i>Rheumatology</i> , 2021, 60, 2635-2646.	1.9	16
10	Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 178-185.	1.1	17
11	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. <i>International Journal of Clinical Practice</i> , 2021, 75, e13819.	1.7	1
12	The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 418-426.	9.1	14
13	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 2472-2477.	1.9	20
14	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 21.	3.5	14
15	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. <i>Frontiers in Immunology</i> , 2021, 12, 580271.	4.8	3
16	Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 152.	2.7	8
17	Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 102.	3.5	10
18	Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: A longitudinal cohort study in Zhengzhou during 2017-2019. <i>EBioMedicine</i> , 2021, 68, 103398.	6.1	8

#	ARTICLE	IF	CITATIONS
19	Characteristics and Outcomes of Coronary Artery Involvement in Polyarteritis Nodosa. Canadian Journal of Cardiology, 2021, 37, 895-903.	1.7	8
20	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. Clinical Rheumatology, 2021, 40, 4589-4596.	2.2	4
21	Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage. Journal of Autoimmunity, 2021, 122, 102650.	6.5	6
22	Comparison of pathological findings between patients with relapsed and non-relapsed immunoglobulin G4-related disease. Chinese Medical Journal, 2021, Publish Ahead of Print, .	2.3	0
23	Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease. Frontiers in Immunology, 2021, 12, 747076.	4.8	7
24	Comparison of relapsing polychondritis patients with and without central nervous system involvement: A retrospective study of 181 patients. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110005.	2.1	9
25	UPLC-MS based plasma metabolomics and lipidomics reveal alterations associated with IgG4-related disease. Rheumatology, 2021, 60, 3252-3261.	1.9	4
26	Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. Emerging Microbes and Infections, 2021, 10, 2303-2312.	6.5	10
27	Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort. Frontiers in Medicine, 2021, 8, 784520.	2.6	5
28	Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients. BMC Ophthalmology, 2021, 21, 447.	1.4	3
29	Management of immune checkpoint inhibitorâ€related dermatologic adverse events. Thoracic Cancer, 2020, 11, 488-492.	1.9	17
30	Management of immune checkpoint inhibitorâ€related rheumatic adverse events. Thoracic Cancer, 2020, 11, 198-202.	1.9	2
31	Clinical diagnosis and treatment of immune checkpoint inhibitorâ€associated pneumonitis. Thoracic Cancer, 2020, 11, 191-197.	1.9	52
32	Clinical manifestation and management of immune checkpoint inhibitorâ€associated cardiotoxicity. Thoracic Cancer, 2020, 11, 475-480.	1.9	9
33	Use of glucocorticoids in the management of immunotherapyâ€related adverse effects. Thoracic Cancer, 2020, 11, 3047-3052.	1.9	13
34	Clinical features and longâ€term outcomes of Chinese patients with scleroderma renal crisis. International Journal of Rheumatic Diseases, 2020, 23, 1194-1200.	1.9	3
35	Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study. Arthritis Research and Therapy, 2020, 22, 255.	3.5	18
36	Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population. Frontiers in Medicine, 2020, 7, 583944.	2.6	12

#	ARTICLE	IF	CITATIONS
37	Clinical manifestations of Behçet's disease in a large cohort of Chinese patients: gender- and age-related differences. <i>Clinical Rheumatology</i> , 2020, 39, 3449-3454.	2.2	8
38	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , 2020, 11, 829-834.	1.9	5
39	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020, 11, 799-804.	1.9	24
40	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020, 11, 810-818.	1.9	19
41	Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , 2020, 11, 1099-1104.	1.9	5
42	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020, 11, 805-809.	1.9	8
43	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	1.9	10
44	Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans. <i>Journal of Infection</i> , 2020, 80, 310-319.	3.3	9
45	Systemic lupus erythematosus gastrointestinal involvement: a computed tomography-based assessment. <i>Scientific Reports</i> , 2020, 10, 6400.	3.3	6
46	Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1479-1488.	1.9	17
47	The Clinical Features and Risk Factors of Parenchymal Neuro-Behçet's Disease. <i>Journal of Immunology Research</i> , 2019, 2019, 1-7.	2.2	8
48	Effectiveness and safety of interferon γ 2a as an add-on treatment for refractory Behçet's uveitis. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984788.	2.5	12
49	Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy. <i>Arthritis Research and Therapy</i> , 2019, 21, 44.	3.5	18
50	The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behçet's Disease. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	2.2	14
51	Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet's disease: a single-centre experience in China. <i>Rheumatology</i> , 2018, 57, 2057-2059.	1.9	13
52	The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 171-175.	0.8	13
53	Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. <i>Rheumatology</i> , 2015, 54, 1982-1990.	1.9	185
54	The clinical features, image findings and risk factors of vena cava syndrome in Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, .	0.8	2